The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer

Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we ev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2013-06, Vol.30 (2), p.551-551, Article 551
Hauptverfasser:	Ustaalioglu, Bala Basak Oven, Bilici, Ahmet, Ercan, Serif, Seker, Mesut, Orcun, Asuman, Gumus, Mahmut
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Disease Progression Disease-Free Survival Female Follow-Up Studies Hematology Humans Internal Medicine Keratin-18 - biosynthesis Keratin-18 - blood Lung cancer Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pathology Peptide Fragments - biosynthesis Peptide Fragments - blood Prognosis Survival Rate - trends Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!